Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study
7.5
来源：
Cell
关键字：
point-of-care diagnostics
发布时间：
2025-09-05 03:34
摘要：
A multicenter, randomized, double-blind, placebo-controlled trial evaluated the effects of henagliflozin, an SGLT2 inhibitor, on aging biomarkers in patients with type 2 diabetes. The study found that henagliflozin significantly increased telomere length and improved glucose metabolism, suggesting potential anti-aging effects. Additionally, it influenced immune cell function and various metabolites, indicating a multifaceted approach to delaying aging in diabetic patients. The findings highlight the drug's promise in addressing age-related diseases and improving overall healthspan.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.5
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
Henagliflozin significantly increases telomere length (primary endpoint).
The study shows that henagliflozin can lead to changes in various metabolites.
This trial is registered at Chinese Clinical Trial Registry (ChiCTR2300068127).
真实性检查
否
AI评分总结
A multicenter, randomized, double-blind, placebo-controlled trial evaluated the effects of henagliflozin, an SGLT2 inhibitor, on aging biomarkers in patients with type 2 diabetes. The study found that henagliflozin significantly increased telomere length and improved glucose metabolism, suggesting potential anti-aging effects. Additionally, it influenced immune cell function and various metabolites, indicating a multifaceted approach to delaying aging in diabetic patients. The findings highlight the drug's promise in addressing age-related diseases and improving overall healthspan.